← → Navigate · ESC Overview
Investor Presentation · 2026
01 / 21

ORVANA

Oral Microbiome Intelligence

Confidential
01 / 21
Orvana · 2026
02 / 21
THE PROBLEM

THE MOUTH IS THE MOST OVERLOOKED ORGAN IN HEALTHCARE

People worldwide suffer from oral disease — yet systemic links go undiagnosed
3.5B
Of systemic diseases have oral manifestations, including diabetes, heart disease, and Alzheimer's
90%
Existing diagnostic tools dedicated to oral microbiome profiling at clinical scale
$0
Standard care is reactive. By the time oral disease is detected, systemic damage is already underway.
Orvana · Oral Microbiome Intelligence
02 / 21
Orvana · 2026
03 / 21
OUR SOLUTION

PRECISION ORAL MICROBIOME DIAGNOSTICS

Orvana sequences and analyses the full oral microbiome, delivering personalised health intelligence to consumers and clinicians across Southeast Asia — starting with Malaysia, Indonesia, and the Philippines.

01
16S rRNA Sequencing
NGS-based profiling of 700+ oral microbial species via certified lab partners
02
AI Risk Stratification
Predictive scoring models trained on published microbiome research literature
03
Consumer + Provider
Direct-to-consumer test kits and a clinician-facing report dashboard
Orvana · Oral Microbiome Intelligence
03 / 21
Orvana · 2026
04 / 21
WHY NOW

THREE TAILWINDS ARE CONVERGING

SEQUENCING COSTS
DOWN 99%
WGS costs have dropped from $100M to under $600 per sample since 2001. Clinical-scale microbiome sequencing is now economically viable for consumer-grade products.
AI DIAGNOSTICS
MATURING
Regulatory and scientific frameworks for AI-assisted microbiome diagnostics are developing rapidly across the US, EU, and Asia-Pacific.
ORAL-SYSTEMIC LINK
PROVEN
200+ peer-reviewed studies confirm connections between oral microbiome composition and systemic diseases including diabetes, cardiovascular disease, and Alzheimer's.
Orvana · Oral Microbiome Intelligence
04 / 21
Orvana · 2026
05 / 21
MARKET OPPORTUNITY

A $42B MARKET WAITING TO BE UNLOCKED

Total Addressable Market Global oral diagnostics, 2025
$6.2B
Serviceable Addressable Market SEA oral diagnostics & wellness
$1.1B
TARGET MARKETS
Malaysia · Indonesia Philippines

680M+ population. Rising health awareness & underpenetrated diagnostics — SEA first-mover advantage.
Growth Drivers
01
Rising preventive health spending across SEA middle class
02
Microbiome testing market growing at 18% CAGR through 2030
03
Direct-to-consumer health diagnostics normalised post-COVID

We are building the first oral microbiome diagnostic platform purpose-built for Southeast Asia.

Adjacent expansion: cardiovascular risk screening, metabolic health, and oncology markers — all accessible through oral microbiome signals.

Orvana · Oral Microbiome Intelligence
05 / 21
Orvana · 2026
06 / 21
PRODUCT PLATFORM

FROM SALIVA SAMPLE TO CLINICAL
INSIGHT

01
Sample Collection
Patient swabs at home or in-clinic in under 2 minutes
02
Sequencing Lab
NGS 16S rRNA sequencing via NovogeneAIT Genomics & Science Werks
03
AI Analysis
Risk scoring across 12 disease-linked microbial signatures
04
Insight Report
Personalised report delivered digitally within 48 hours

ORVANA CORE

Consumer portal — test kit order, report delivery, personalised recommendations

ORVANA CLINIC

Clinician dashboard — patient tracking, longitudinal microbiome monitoring

ORVANA INSIGHTS

Population health analytics for corporate wellness and research partners

Orvana · Oral Microbiome Intelligence
06 / 21
Orvana · 2026
07 / 21
THE SCIENCE

BUILT ON PUBLISHED MICROBIOME RESEARCH

Orvana's diagnostic model is built on peer-reviewed microbiome science. Our biomarker selection draws from the published literature, and our sequencing methodology follows validated NGS protocols used in clinical research settings.

Sensitivity for caries risk (published literature range)
94%
Specificity for periodontal pathogens (published range)
91%
28 species-level signatures linked to caries, periodontitis, endodontic infection, cardiovascular disease, and T2 diabetes — drawn from published clinical microbiome studies.Biomarker Framework
16S rRNA NGS sequencing conducted via NovogeneAIT Genomics (MOU signed) and Science Werks. Lab validation and Singapore regulatory review underway.Sequencing Partnership
Orvana · Oral Microbiome Intelligence
07 / 21
Orvana · 2026
08 / 21
TRACTION

EARLY MOMENTUM. REAL PARTNERS. REAL DEMAND.

NovogeneAIT Genomics
NGS 16S rRNA sequencing partner — Singapore. Processing agreement in place for sample pipeline.
MOU SIGNED
Science Werks
Singapore-based lab partner for sample processing, QC, and regulatory compliance support.
MOU SIGNED
A*STAR IHDP
Initial meeting confirmed with Vidhya (A*STAR IHDP) to explore oral microbiome database collaboration.
MEETING CONFIRMED
Test Kit Price
US$99
Direct-to-consumer
Subscription
US$55/mo
Probiotic protocol kit
LTV : CAC
6.2×
LTV $528 / CAC $85
Break-Even
Month 10
Subscription-funded
Orvana · Oral Microbiome Intelligence
08 / 21
Orvana · 2026
09 / 21
BUSINESS MODEL

THREE RECURRING REVENUE STREAMS

TEST KIT
US$99 · Direct-to-consumer, one-time
Entry product — oral microbiome diagnostic. Consumer orders online, swabs at home, receives digital report within 48 hrs.
SUBSCRIPTION
US$55/mo · Probiotic protocol — ongoing
Monthly personalised probiotic, prebiotic rinse & oil pull blend. 55% of kit buyers convert. 6% monthly churn.
RETEST KIT
US$59 · Every 6 months for subscribers
Semi-annual retest for active subscribers. Tracks microbiome changes and protocol effectiveness over time.
Gross Margin
~65%
Lab COGS per test
$32
CAC (Consumer)
$85
LTV (12-month)
$528
Orvana · Oral Microbiome Intelligence
09 / 21
Orvana · 2026
10 / 21
GO-TO-MARKET

DIRECT-TO-CONSUMER. THEN ENTERPRISE.

PHASE 1
DTC Launch · NOW → 2025
Online-first. Singapore launch via e-commerce. Influencer seeding, paid social, SEA health KOLs. Founder's Cohort of 50 early adopters.
PHASE 2
SEA Expansion · 2026
Malaysia, Indonesia, Philippines market entry. Corporate wellness channel. Clinic partnerships in primary care and dental.
PHASE 3
Enterprise & Health Systems · 2027+
Population health contracts with insurers, hospitals, and corporate health networks. White-label API licensing.
DTC via Shopify + social commerce (ACV $99–$758/yr per subscriber). Corporate wellness outreach to HR leads at 50 target companies. Dental clinic partnerships as referral channel.Sales Motion
SEA Addressable Consumers
680M+
Year 1 Target Customers
1,380
Year 3 Revenue Target
$3.1M
Orvana · Oral Microbiome Intelligence
10 / 21
Orvana · 2026
11 / 21
COMPETITIVE LANDSCAPE

NO DIRECT COMPETITOR IN SEA

Company
SEA?
Systemic?
Consumer?
Orvana
Yes
Yes
Yes
OralDNA Labs
No
Limited
No
Viome
Limited
Gut only
Yes
CMBio / Nirvana
Partial
No
No
SEA-first product — Singapore HQ, regional lab network / Lab MOUs with NovogeneAIT & Science Werks / A*STAR IHDP engagement for database collaboration / Consumer clinician dual channel from Day 1Our Moat
Each sample added enriches our SEA oral microbiome dataset. First-mover data advantage compounds with scale and creates a proprietary regional reference database.Defensibility
Orvana · Oral Microbiome Intelligence
11 / 21
Orvana · 2026
12 / 21
FINANCIAL PROJECTIONS

PATH TO $3.1M REVENUE BY YEAR 3

477
Year 1
1,447
Year 2
3,092
Year 3
Gross Margin Y3
78%
EBITDA Breakeven
Month 10
LTV : CAC
6.2×

Revenue Mix (Year 3)

Test Kit Sales
$653K
21%
Subscriptions
$2,257K
73%
Retest Kits
$182K
6%

Key Assumptions

1,380 kit buyers in Year 1 → 6,600 by Year 3

55% kit-to-subscription conversion rate

45% of subscribers retest semi-annually

Note: These projections reflect the pre-seed consumer/SEA model. Enterprise & health system revenue layer begins in Phase 3 (2027+) and is modelled separately.

Orvana · Oral Microbiome Intelligence
12 / 21
Orvana · 2026
13 / 21
PRE-SEED CAPITAL STRATEGY · CONFIDENTIAL

STARTUP COST BREAKDOWN

Marketing Launch
Influencer, paid social, PR
$125,400
Initial Inventory
3-month buffer stock
$94,050
Product Formulation
R&D, sampling, HSA review
$78,375
Branding & Website
Identity, Shopify, copywriting
$62,700
Lab Partner Setup
NovogeneAIT, Science Werks, QC
$47,025
Legal & Regulatory
Terms, privacy, compliance
$47,025
Contingency (10%)
Buffer for overruns
$45,425
Target Raise
US$500,000
SAFE · 20% disc · S$5M cap
Total Startup Capital
$500,000
Test Kit
US$99
Subscription
US$55/mo
Gross Margin
~65%
Series A Target
$8–12M
Monthly Burn Pre-Revenue
$18,000
Salaries + fixed OpEx
LTV : CAC Ratio
6.2×
LTV $528 / CAC $85
Break-Even Month
Month 10
Subscriptions cover costs
CAC Payback Period
~9 months
Recovers in under 1 year
Orvana · Oral Microbiome Intelligence
13 / 21
Orvana · 2026
14 / 21
LEADERSHIP

FOUNDER-LED. SCIENCE-DRIVEN.

Gideon Agus Nuswantoro

FOUNDER & CEO

Founder of Orvana Health — Singapore-based oral microbiome diagnostics startup. Over 20 years of experience across marketing, brand development, consumer business, operations, and multi-venture portfolio management. Founder and CEO of Aviel Investment Pte. Ltd., a Singapore-incorporated holding platform with Indonesian infrastructure and energy focus. Proven track record in building investor-ready companies from the ground up.

Why I'm Building Orvana
The oral microbiome is the most accessible, most underserved diagnostic frontier in medicine — and Southeast Asia has no solution built for it yet. Orvana exists to change that. Starting in Singapore, scaling across the region.
Gideon Agus Nuswantoro
Orvana · Oral Microbiome Intelligence
14 / 21
Orvana · 2026
15 / 21
LEADERSHIP

TECHNOLOGY LEADERSHIP

Sagit Hariaji

CO-FOUNDER & CTO

Background
Technology leader with 9 years of experience in Indonesia's IT industry, focused on building and scaling enterprise solutions for the Food & Beverage and manufacturing sectors. As a founder, CTO, and business analyst, Sagit has led the development of ERP systems that streamline operations across finance, inventory, supply chain, and production. His strength lies in bridging business needs with technology execution — designing practical, scalable systems that improve efficiency and support long-term growth.

At Orvana, Sagit leads platform architecture, lab data pipeline, bioinformatics tooling, and the consumer-facing digital stack.

Sagit Hariaji
Orvana · Oral Microbiome Intelligence
15 / 21
Orvana · 2026
16 / 21
LEADERSHIP

HEALTH & PARTNERSHIPS

Carla

CO-FOUNDER & HEAD OF HEALTH

Background
10+ years of experience in the healthcare and life sciences sector across Singapore and the Philippines, spanning clinical operations, health programme management, preventive healthcare, diagnostics, and corporate wellness. Previously held senior leadership roles within a Singapore-based integrated healthcare network, where she led patient engagement initiatives, managed clinical partnerships, and drove preventive health programmes across corporate and community settings. She also serves as a Lead Physician for a Philippines-based clinical laboratory and healthcare clinic, overseeing clinical operations, quality standards, patient care, and healthcare partnerships. Experienced in healthcare quality improvement, operational strategy, and stakeholder engagement, with a strong focus on advancing accessible, science-driven, and patient-centered healthcare solutions.

Role at Orvana
Leads clinical partnerships, lab partner relations (NovogeneAIT, Science Werks, A*STAR IHDP), regulatory engagement with HSA and MOH Singapore, and the corporate wellness go-to-market channel. Her network within Singapore's healthcare ecosystem is a key strategic asset for Orvana's clinical credibility and channel access.

Carla
Orvana · Oral Microbiome Intelligence
16 / 21
Orvana · 2026
17 / 21
STRATEGIC PARTNERSHIPS

ANCHORED BY KEY RELATIONSHIPS

MOU SIGNED
NOVOGENEAIT GENOMICS
Singapore-based NGS genomics lab. MOU signed covering 16S rRNA sequencing of oral microbiome samples. Competitive per-sample pricing agreed for pilot and scale-up phases.

Primary sequencing partner — Singapore
MOU SIGNED
SCIENCE WERKS
Singapore laboratory services partner. Agreement covering sample processing, DNA extraction, QC protocols, and regulatory compliance support for HSA requirements.

Lab processing & QC partner — Singapore
MEETING CONFIRMED
A*STAR IHDP
Agency for Science, Technology & Research — Institute for Human Development & Potential. Meeting confirmed with Vidhya (IHDP) to explore collaboration on Singapore oral microbiome reference database.

Research database collaboration — Singapore
IN PIPELINE
CORPORATE WELLNESS
Outreach underway to HR leads at 50 Singapore and SEA-headquartered corporates. Targeting group wellness package adoption as a B2B revenue layer alongside DTC channel.

B2B channel — Singapore & regional
Orvana · Oral Microbiome Intelligence
17 / 21
Orvana · 2026
18 / 21
PRODUCT ROADMAP

PROJECT EXECUTION MILESTONES 2025–2027

2025
Pre-Seed Close
US$500K SAFE · S$5M cap · SGP & angel investors
Lab Agreements Final
NovogeneAIT & Science Werks fully contracted
Product Launch
DTC via Shopify · Founder's Cohort of 50 customers
2026
SEA Expansion
Malaysia, Indonesia, Philippines market entry
A*STAR Collaboration
Oral microbiome database research programme
Corporate Wellness
50-company B2B outreach · Group wellness contracts
2027
Series A — $8–12M
300+ paying customers · proven LTV:CAC
Enterprise Layer
Health systems, insurers, population health API
International Expansion
ANZ + Hong Kong · referral programme at scale
Orvana · Oral Microbiome Intelligence
18 / 21
Orvana · 2026
19 / 21
THE ASK

PRE-SEED — $500K TO BUILD THE FOUNDATION

US$500,000
Pre-Seed Target

SAFE · 20% discount · S$5M valuation cap

Use of Proceeds

Marketing launch — influencer, PR, paid social25%
Initial inventory — kit & supplement buffer19%
Product formulation & R&D16%
Branding, website & Shopify13%
Lab partner setup — NovogeneAIT, Science Werks9%
Legal, regulatory & contingency18%

Valuation Cap

S$5M

SAFE · 20% discount · No maturity

What You're Backing

Lab MOUs signed.
Team in place.
Product in build.

Next Milestone → Series A

$8–12M at 300+ paying customers
Orvana · Oral Microbiome Intelligence
19 / 21
Orvana · 2026
20 / 21
SOCIAL RESPONSIBILITY

HEALTH ACCESS IS
A RIGHT, NOT A PRIVILEGE.

AFFORDABLE DIAGNOSTICS

Price Parity for SEA

Our US$99 test kit is priced at ~20–30% of comparable Western diagnostics. Volume commitments with NovogeneAIT & Science Werks enable cost reduction as we scale — targeting sub-$70 per test by Year 2.

COMMUNITY HEALTH DATA

A Database for the Region

Every anonymised sample enriches SEA's first oral microbiome reference database — filling a critical scientific gap. This population dataset will be made available for public health research via our A*STAR IHDP collaboration.

UNDERSERVED POPULATIONS

Beyond the Urban Core

Phase 2 targets rural Malaysia, Indonesia, and the Philippines — populations with high oral disease burden and near-zero diagnostic access. B2B corporate wellness pricing subsidises community outreach kits at reduced cost.

Orvana's mission: make precision oral health intelligence accessible to every person in Southeast Asia — not just those who can already afford premium care.
Orvana · Oral Microbiome Intelligence
20 / 21
The Opportunity
21 / 21
THE OPPORTUNITY

THE MOUTH IS A WINDOW.
WE BUILT THE LENS.

Orvana is building the standard for oral microbiome diagnostics in Southeast Asia. Lab partners secured. Team assembled. First customers in sight. We're raising the round to launch.

GIDEON AGUS NUSWANTORO
Founder & CEO, Orvana Healthgideon@orvana.health · orvana.health
Confidential — 2026
21 / 21